

DDO-2093 biochemical

DDO-2093

CATALOG #
AAA228261


PRODUCT SYNONYMS

DDO-2093; DDO-2093 biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	2250024-74-7
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	DDO-2093 (20 mg/kg-80 mg/kg; i.p.; every other day for 21 days) significantly suppresses the tumor size and weight in a dose-dependent manner[1]. Animal Model: Female nude mice (MV4-11 human leukemia cancer xenografts)[1]. Dosage: 20 mg/kg, 40 mg/kg and 80 mg/kg. Administration: I.p.; every other day for 21 days. Result: The tumor volume growth inhibition (GI) values were calculated to be 13.7%, 37.6% and 63.9% with doses of 20 mg/kg, 40 mg/kg and 80 mg/kg, respectively.
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
AB-729, CAS 2634739-74-3



Structure
AB-729, CAS 2634739-74-3

ADDITIONAL INFORMATION

Related Product Information for DDO-2093 biochemical	DDO-2093 is a potent MLL1-WDR5 protein-protein interaction inhibitor (IC ₅₀ =8.6 nM; K _d =11.6 nM) with antitumor activity. DDO-2093 selectively inhibits the catalytic activity of MLL complex.
References	1. Efthymios P Tsounis, et al. Toward a new era of hepatitis B virus therapeutics: The pursuit of a functional cure. World J Gastroenterol. 2021 Jun 7;27(21):2727-2757. 2. Arbutus Receives Authorization to Proceed with an Investigational New Drug Application (IND) for AB-729, its Proprietary Subcutaneously-Delivered RNAi Agent.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com
Online datasheet: <https://stage.aaabiotech.com/biochemical/ddo-2093/228261>